Prognostic model for mantle cell lymphoma in the rituximab era

A nationwide study in Japan

Dai Chihara, Naoko Asano, Ken Ohmachi, Tomohiro Kinoshita, Masataka Okamoto, Yoshinobu Maeda, Ishikazu Mizuno, Kosei Matsue, Toshiki Uchida, Hirokazu Nagai, Momoko Nishikori, Shigeo Nakamura, Michinori Ogura, Ritsuro Suzuki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) is essentially incurable with conventional chemotherapy. The MCL International Prognostic Index (MIPI) is a validated specific prognostic index, but was derived from patients with advanced-stage disease primarily in the pre-rituximab era. We analysed 501 MCL patients (median age, 67 years; range 22-90) treated with rituximab-containing chemotherapy, and evaluated the prognostic factors adjusted by the treatment. Five-year overall survival (OS) in the low, intermediate and high MIPI groups was 74%, 70% and 35%, respectively. Additional to MIPI risk factors, multivariate analysis revealed that low serum albumin and bone-marrow involvement were also significantly associated with a poor outcome. The revised-MIPI (R-MIPI) was constructed using six factors, namely age, performance status, white blood cell count, serum lactate dehydrogenase, bone-marrow involvement and serum albumin, which is divided into four prognostic groups. Five-year OS in low, low-intermediate (L-I), high-intermediate (H-I) and high R-MIPI groups was 92%, 75%, 61% and 19%, respectively. Hazard ratio for OS of L-I, H-I and high risk to low risk patients were 5·4, 8·3 and 33·0, respectively. R-MIPI, a new prognostic index with easy application to the general patient population, shows promise for identifying low- and high-risk MCL patients in the rituximab era.

Original languageEnglish
Pages (from-to)657-668
Number of pages12
JournalBritish Journal of Haematology
Volume170
Issue number5
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Mantle-Cell Lymphoma
Japan
Serum Albumin
Survival
Bone Marrow
Drug Therapy
Age Factors
Leukocyte Count
L-Lactate Dehydrogenase
Statistical Factor Analysis
Multivariate Analysis
Rituximab
Serum
Population

Keywords

  • Mantle cell lymphoma
  • MIPI
  • Prognostic factor
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Prognostic model for mantle cell lymphoma in the rituximab era : A nationwide study in Japan. / Chihara, Dai; Asano, Naoko; Ohmachi, Ken; Kinoshita, Tomohiro; Okamoto, Masataka; Maeda, Yoshinobu; Mizuno, Ishikazu; Matsue, Kosei; Uchida, Toshiki; Nagai, Hirokazu; Nishikori, Momoko; Nakamura, Shigeo; Ogura, Michinori; Suzuki, Ritsuro.

In: British Journal of Haematology, Vol. 170, No. 5, 01.09.2015, p. 657-668.

Research output: Contribution to journalArticle

Chihara, D, Asano, N, Ohmachi, K, Kinoshita, T, Okamoto, M, Maeda, Y, Mizuno, I, Matsue, K, Uchida, T, Nagai, H, Nishikori, M, Nakamura, S, Ogura, M & Suzuki, R 2015, 'Prognostic model for mantle cell lymphoma in the rituximab era: A nationwide study in Japan', British Journal of Haematology, vol. 170, no. 5, pp. 657-668. https://doi.org/10.1111/bjh.13486
Chihara, Dai ; Asano, Naoko ; Ohmachi, Ken ; Kinoshita, Tomohiro ; Okamoto, Masataka ; Maeda, Yoshinobu ; Mizuno, Ishikazu ; Matsue, Kosei ; Uchida, Toshiki ; Nagai, Hirokazu ; Nishikori, Momoko ; Nakamura, Shigeo ; Ogura, Michinori ; Suzuki, Ritsuro. / Prognostic model for mantle cell lymphoma in the rituximab era : A nationwide study in Japan. In: British Journal of Haematology. 2015 ; Vol. 170, No. 5. pp. 657-668.
@article{28ad2c3f8cb2458bac24ebdb6dc6b0dd,
title = "Prognostic model for mantle cell lymphoma in the rituximab era: A nationwide study in Japan",
abstract = "Mantle cell lymphoma (MCL) is essentially incurable with conventional chemotherapy. The MCL International Prognostic Index (MIPI) is a validated specific prognostic index, but was derived from patients with advanced-stage disease primarily in the pre-rituximab era. We analysed 501 MCL patients (median age, 67 years; range 22-90) treated with rituximab-containing chemotherapy, and evaluated the prognostic factors adjusted by the treatment. Five-year overall survival (OS) in the low, intermediate and high MIPI groups was 74{\%}, 70{\%} and 35{\%}, respectively. Additional to MIPI risk factors, multivariate analysis revealed that low serum albumin and bone-marrow involvement were also significantly associated with a poor outcome. The revised-MIPI (R-MIPI) was constructed using six factors, namely age, performance status, white blood cell count, serum lactate dehydrogenase, bone-marrow involvement and serum albumin, which is divided into four prognostic groups. Five-year OS in low, low-intermediate (L-I), high-intermediate (H-I) and high R-MIPI groups was 92{\%}, 75{\%}, 61{\%} and 19{\%}, respectively. Hazard ratio for OS of L-I, H-I and high risk to low risk patients were 5·4, 8·3 and 33·0, respectively. R-MIPI, a new prognostic index with easy application to the general patient population, shows promise for identifying low- and high-risk MCL patients in the rituximab era.",
keywords = "Mantle cell lymphoma, MIPI, Prognostic factor, Rituximab",
author = "Dai Chihara and Naoko Asano and Ken Ohmachi and Tomohiro Kinoshita and Masataka Okamoto and Yoshinobu Maeda and Ishikazu Mizuno and Kosei Matsue and Toshiki Uchida and Hirokazu Nagai and Momoko Nishikori and Shigeo Nakamura and Michinori Ogura and Ritsuro Suzuki",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/bjh.13486",
language = "English",
volume = "170",
pages = "657--668",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Prognostic model for mantle cell lymphoma in the rituximab era

T2 - A nationwide study in Japan

AU - Chihara, Dai

AU - Asano, Naoko

AU - Ohmachi, Ken

AU - Kinoshita, Tomohiro

AU - Okamoto, Masataka

AU - Maeda, Yoshinobu

AU - Mizuno, Ishikazu

AU - Matsue, Kosei

AU - Uchida, Toshiki

AU - Nagai, Hirokazu

AU - Nishikori, Momoko

AU - Nakamura, Shigeo

AU - Ogura, Michinori

AU - Suzuki, Ritsuro

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Mantle cell lymphoma (MCL) is essentially incurable with conventional chemotherapy. The MCL International Prognostic Index (MIPI) is a validated specific prognostic index, but was derived from patients with advanced-stage disease primarily in the pre-rituximab era. We analysed 501 MCL patients (median age, 67 years; range 22-90) treated with rituximab-containing chemotherapy, and evaluated the prognostic factors adjusted by the treatment. Five-year overall survival (OS) in the low, intermediate and high MIPI groups was 74%, 70% and 35%, respectively. Additional to MIPI risk factors, multivariate analysis revealed that low serum albumin and bone-marrow involvement were also significantly associated with a poor outcome. The revised-MIPI (R-MIPI) was constructed using six factors, namely age, performance status, white blood cell count, serum lactate dehydrogenase, bone-marrow involvement and serum albumin, which is divided into four prognostic groups. Five-year OS in low, low-intermediate (L-I), high-intermediate (H-I) and high R-MIPI groups was 92%, 75%, 61% and 19%, respectively. Hazard ratio for OS of L-I, H-I and high risk to low risk patients were 5·4, 8·3 and 33·0, respectively. R-MIPI, a new prognostic index with easy application to the general patient population, shows promise for identifying low- and high-risk MCL patients in the rituximab era.

AB - Mantle cell lymphoma (MCL) is essentially incurable with conventional chemotherapy. The MCL International Prognostic Index (MIPI) is a validated specific prognostic index, but was derived from patients with advanced-stage disease primarily in the pre-rituximab era. We analysed 501 MCL patients (median age, 67 years; range 22-90) treated with rituximab-containing chemotherapy, and evaluated the prognostic factors adjusted by the treatment. Five-year overall survival (OS) in the low, intermediate and high MIPI groups was 74%, 70% and 35%, respectively. Additional to MIPI risk factors, multivariate analysis revealed that low serum albumin and bone-marrow involvement were also significantly associated with a poor outcome. The revised-MIPI (R-MIPI) was constructed using six factors, namely age, performance status, white blood cell count, serum lactate dehydrogenase, bone-marrow involvement and serum albumin, which is divided into four prognostic groups. Five-year OS in low, low-intermediate (L-I), high-intermediate (H-I) and high R-MIPI groups was 92%, 75%, 61% and 19%, respectively. Hazard ratio for OS of L-I, H-I and high risk to low risk patients were 5·4, 8·3 and 33·0, respectively. R-MIPI, a new prognostic index with easy application to the general patient population, shows promise for identifying low- and high-risk MCL patients in the rituximab era.

KW - Mantle cell lymphoma

KW - MIPI

KW - Prognostic factor

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84938949995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938949995&partnerID=8YFLogxK

U2 - 10.1111/bjh.13486

DO - 10.1111/bjh.13486

M3 - Article

VL - 170

SP - 657

EP - 668

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -